

James M Angelastro

List of Publications by Citations

Source: <https://exaly.com/author-pdf/292798/james-m-angelastro-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35 papers	1,610 citations	19 h-index	36 g-index
36 ext. papers	1,752 ext. citations	6 avg, IF	4.34 L-index

#	Paper	IF	Citations
35	Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. <i>Journal of Neuroscience</i> , 2002 , 22, 10690-8	6.6	457
34	Death in the balance: alternative participation of the caspase-2 and -9 pathways in neuronal death induced by nerve growth factor deprivation. <i>Journal of Neuroscience</i> , 2001 , 21, 5007-16	6.6	126
33	Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. <i>Journal of Neuroscience</i> , 2003 , 23, 4590-600	6.6	106
32	Analysis of gene expression changes in a cellular model of Parkinson disease. <i>Neurobiology of Disease</i> , 2005 , 18, 54-74	7.5	74
31	Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. <i>Oncogene</i> , 2006 , 25, 907-16	9.2	70
30	Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. <i>Journal of Neuroscience</i> , 2005 , 25, 3889-99	6.6	69
29	The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. <i>International Journal of Cancer</i> , 2007 , 120, 1883-90	7.5	67
28	Premutation CCG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. <i>Human Molecular Genetics</i> , 2011 , 20, 64-79	5.6	65
27	Overexpression of CD133 promotes drug resistance in C6 glioma cells. <i>Molecular Cancer Research</i> , 2010 , 8, 1105-15	6.6	62
26	The transcription factor ATF5: role in neurodevelopment and neural tumors. <i>Journal of Neurochemistry</i> , 2009 , 108, 11-22	6	60
25	ATF5 regulates the proliferation and differentiation of oligodendrocytes. <i>Molecular and Cellular Neurosciences</i> , 2005 , 29, 372-80	4.8	53
24	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 4698-711	12.9	52
23	The basic region and leucine zipper transcription factor MafK is a new nerve growth factor-responsive immediate early gene that regulates neurite outgrowth. <i>Journal of Neuroscience</i> , 2002 , 22, 8971-80	6.6	39
22	Characterization of a novel isoform of caspase-9 that inhibits apoptosis. <i>Journal of Biological Chemistry</i> , 2001 , 276, 12190-200	5.4	34
21	Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. <i>Molecular Cancer Research</i> , 2009 , 7, 933-43	6.6	32
20	Nerve growth factor selectively regulates expression of transcripts encoding ribosomal proteins. <i>BMC Neuroscience</i> , 2002 , 3, 3	3.2	29
19	The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. <i>Oncotarget</i> , 2017 , 8, 84595-84609	3.3	23

18	Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007 , 85, 149-57	4.8	22
17	Peripherin is tyrosine-phosphorylated at its carboxyl-terminal tyrosine. <i>Journal of Neurochemistry</i> , 1998 , 70, 540-9	6	19
16	Tyrosine phosphorylation of extracellular signal-regulated protein kinase 4 in response to growth factors. <i>Journal of Neurochemistry</i> , 1996 , 66, 1191-7	6	18
15	You can't go home again: transcriptionally driven alteration of cell signaling by NGF. <i>Neurochemical Research</i> , 2005 , 30, 1347-52	4.6	18
14	Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide. <i>Oncotarget</i> , 2016 , 7, 12718-30	3.3	18
13	Targeting ATF5 in Cancer. <i>Trends in Cancer</i> , 2017 , 3, 471-474	12.5	17
12	Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD. <i>Molecular Cancer Research</i> , 2020 , 18, 216-228	6.6	13
11	PRMT1 promotes neuroblastoma cell survival through ATF5. <i>Oncogenesis</i> , 2020 , 9, 50	6.6	10
10	Expression and targeting of transcription factor ATF5 in dog gliomas. <i>Veterinary and Comparative Oncology</i> , 2018 , 16, 102-107	2.5	9
9	Reciprocal actions of ATF5 and Shh in proliferation of cerebellar granule neuron progenitor cells. <i>Developmental Neurobiology</i> , 2012 , 72, 789-804	3.2	8
8	Apparently irreversible GTP hydrolysis attends tubulin self-assembly. <i>FEBS Journal</i> , 1990 , 191, 507-11		8
7	Dominant-negative ATF5 rapidly depletes survivin in tumor cells. <i>Cell Death and Disease</i> , 2019 , 10, 709	9.8	6
6	Evidence against impaired brain microtubule protein polymerization at high glucose concentrations or during diabetes mellitus. <i>Journal of Neurochemistry</i> , 1991 , 56, 2087-93	6	6
5	Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 133, 111058	7.5	6
4	Adenine and guanine nucleotide content of Triton-extracted cytoskeletal fractions of nonmuscle cells. <i>Analytical Biochemistry</i> , 1992 , 204, 47-52	3.1	4
3	Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer. <i>Mitochondrion</i> , 2020 , 50, 19-24	4.9	4
2	Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	3
1	Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents. <i>Cancers</i> , 2021 , 13,	6.6	3

